The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Trial Profile

The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Cobicistat; Ritonavir
  • Indications HIV infections; Thromboembolism
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Sep 2017 Results assessing the influence of abcb1 single nucleotide polymorphisms on dabigatran exposure alone and in combination with ritonavir and cobicistat, published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology, ACCP 2017.
    • 28 Aug 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top